Opinion|Videos|November 15, 2024
Disease Severity and Delays in Treatment in CSU
Key Takeaways
- UAS7 and UCT are essential tools for assessing CSU severity and control, aiding in treatment decisions.
- Delayed diagnosis of CSU is frequent, often due to symptom overlap and lack of awareness.
Panelists discuss how disease severity in chronic spontaneous urticaria (CSU) is assessed using tools such as the Urticaria Activity Score over 7 days (UAS7) and the Urticaria Control Test (UCT), while also addressing the frequency of delayed diagnoses and the significant implications for condition management and patient quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How is disease severity assessed?
- UAS7
- UCT
- How frequently do patients receive a delayed diagnosis? What are the implications associated with this delay?
Advertisement
Related to this article
A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.
AAD and HSF issued the first joint hidradenitis suppurativa guidelines, outlining 37 recommendations and flagging step therapy as a major barrier.
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.
At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.
FDA approves bepirovirsen after phase 3 trials show 19% achieved functional cure at 24 weeks off all hepatitis B treatment.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Bepirovirsen for Chronic Hepatitis B
2
TTR and Systolic Blood Pressure Load Control Improve Recurrent Stroke Risk
3
Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD
4
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
5